DGAP-News

MOLOGEN AG: Public rights offering of convertible bonds with purchase guarantee by major shareholder - Seite 3

addition, MOLOGEN completed a significantly oversubscribed capital increase
in October 2016, with gross proceeds of EUR13.6 million.

Important note:
This announcement does not contain or constitute an offer of, or the
solicitation of an offer to buy or subscribe for, securities to any person
in the United States, Australia, Canada, Japan or in any jurisdiction to
whom or in which such offer or solicitation is unlawful. The securities
referred to in this press release have not been, and will not be,
registered under the US Securities Act of 1933, as amended (the "Securities
Act"), and may not be offered or sold in the United States absent
registration or an applicable exemption from registration or in a
transaction not subject to the registration requirements of the Securities
Act. There will be no public offer of the securities in the United States
of America. Subject to certain exceptions under the Securities Act, the
securities referred to herein may not be offered or sold in Australia,
Canada or Japan or to, or for the account or benefit of, any national,
resident or citizen of Australia, Canada or Japan.

MOLOGEN AG
With new and unique technologies and active substances, the biotech company
MOLOGEN is one of the pioneers in the field of immunotherapy. Alongside a
focus on immuno-oncology, MOLOGEN also develops immunotherapies for the
treatment of infectious diseases.

The cancer immunotherapy lefitolimod (MGN1703) is the company's lead
product and best-in-class TLR9 agonist. Treatment with lefitolimod
(MGN1703) triggers a broad and strong activation of the immune system. Due
to this mode of action, namely to reactivate the monitoring function of the
immune system, lefitolimod (MGN1703) can be recognized as an Immune
Surveillance Reactivator (ISR). It has the potential to be applied to
various indications. ISR lefitolimod (MGN1703) is currently being developed
for first-line maintenance treatment of colorectal cancer (pivotal study)
and small cell lung cancer (randomized controlled trial). Furthermore, it
is also being investigated in a phase I study in HIV and a phase I
combination study with the checkpoint inhibitor Yervoy(R) (ipilimumab),
which is expected to start shortly. Next to checkpoint inhibitors,
lefitolimod is one of the few product candidates that are in a phase III
clinical trial (IMPALA) in the field of immuno-oncology and close to
reaching the market.

MOLOGEN's pipeline focus is on new, innovative immunotherapies to treat
diseases for which there is a high medical need.